retatrutide clinical trials weight loss retatrutide Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments First Retatrutide phase 3 data,

Figure S7

Benefits AOD-9604 is believed to help with: Mechanistically designed to support fat breakdown and reduce new fat formation while having minimal direct impact on blood sugar and IGF1. May offer modest additional help with fat metabolism when combined with calorie control and exercise, particularly in higheradiposity individuals. Typically administered as a daily subcutaneous injection in low doses, integrated into a broader metabolic and lifestyle protocol. Longterm clinical safety data show generally good tolerability in studied populations, but regulators have highlighted unresolved immunogenicity and impurity concerns, so usage must remain cautious and fully consented. Positioned as an optional, supportive layernot a standalone weight-loss solutionwith emphasis on lab monitoring, habit coaching, and realistic expectations.

Glutathione is important for skin health, having beneficial effects on protecting cells from oxidative stress that can lead to loss of glow, irregular skin tone and premature ageing

Who should not use semaglutide: Do not use semaglutide if you or any family member has ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)